about
Tumor-specific Th17-polarized cells eradicate large established melanomaStructural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cellsIdentification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapyPreoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunityMurine pancreatic adenocarcinoma reduces Ikaros expression and disrupts T cell homeostasisSleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.T cell survival and function requires the c-Abl tyrosine kinaseTh9 cells promote antitumor immune responses in vivoDevelopment and dynamics of robust T-cell responses to CML under imatinib treatmentT-cell receptor gene therapy for cancer: the progress to date and future objectives.HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor ImmunotherapyHigh-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.Multipeptide vaccination in cancer patients.Testing the theory of immune selection in cancers that break the rules of transplantation.Immune alterations in malignant melanoma and current immunotherapy concepts.Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death.Metastatic melanoma cells evade immune detection by silencing STAT1.A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis.Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model.Roles for common MLL/COMPASS subunits and the 19S proteasome in regulating CIITA pIV and MHC class II gene expression and promoter methylationHuman endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.HLA class II antigen presentation by prostate cancer cells.Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma.Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationThe phenolic profiles of Radix Tetrastigma after solid phase extraction (SPE) and their antitumor effects and antioxidant activities in H22 tumor-bearing mice.Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma.Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy.Adoptive cell therapy against EBV-related malignancies: a survey of clinical resultsImmunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches
P2860
Q24648032-DF969062-F211-4EE7-83CC-1D45964801BFQ27660843-C12FD0CC-4199-4301-A071-FC59A41DF6DDQ30437344-27E482E9-A485-4876-9035-8D15F061C05EQ34111875-37D7CD50-5441-4400-A858-17E899590F98Q34360174-FC7B3371-099C-4E76-A188-368E341C6A21Q35023580-E35FE33B-C170-4DD5-A098-01985FF96D6DQ35962978-460959BC-FA78-4118-A16C-5E808509F394Q36125177-44671236-AD71-406D-96A1-6685854FD0A4Q36357944-3C965C19-CB8D-4D4F-85D6-BA8ECD3B92D4Q36677315-1FCCBED3-DB45-4E71-86C5-D90D93CAABCEQ36909378-78F2985D-A0BE-4789-A1FB-164C0A1748ECQ37252253-F37A124B-BC3D-4B63-9ADC-56D3B4514AAAQ37355703-14A59201-BCB7-40DE-B399-05BFA99D49E9Q37547268-775D3EF3-9340-43EA-848D-20F351DD5CE3Q37662210-55A129CB-765A-46A9-9C8B-6709B5653F91Q38127733-144BC3B0-0FA1-41A2-A9F6-BDA2BC70BB7AQ38863894-F8D663C4-9ABD-4C29-94C7-9038061163A9Q38901228-37028CC9-870A-47BE-B0AF-69F4C36DC0D7Q38908693-88ED9CC5-56DF-42E0-977C-808A5F3E3EC4Q38942384-272EFB31-B905-4E83-81F2-C3CCB9CDC157Q38975033-BD2B3670-CE20-4FA2-B782-1E0BF4209F50Q39313225-86EAD213-D6CD-4C00-B57F-6806113E058AQ39960699-622AACA4-2815-4A9B-9359-AE33613311ADQ40002381-C2C73923-4592-427D-9F55-5DCBF54D514FQ40011550-AA7D93BA-108D-4338-9F68-6131255C54D3Q40067331-E65EFB10-284D-4755-B84A-71CF613DEFFAQ41757247-62057B11-3975-4C87-95B2-72BB1978EAF6Q42233761-A57A52FA-5459-4ECA-9840-D90628597F4DQ42702294-070501DB-873E-4745-817D-ED77610FF266Q47787718-2444AC2C-0557-426F-9418-DB6FE8345805Q50318735-AF75F0E9-57F4-4A7D-A728-AC47369A2C71Q51973490-11E57499-586F-46A6-A99C-3FBDBD7711FDQ57056125-211D31BA-D811-44EF-97A0-623749695CF8Q57732968-A37897CE-99B7-4484-A5EB-145A3EF00F01
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
CD4 T cells in tumor immunity.
@ast
CD4 T cells in tumor immunity.
@en
CD4 T cells in tumor immunity.
@nl
type
label
CD4 T cells in tumor immunity.
@ast
CD4 T cells in tumor immunity.
@en
CD4 T cells in tumor immunity.
@nl
prefLabel
CD4 T cells in tumor immunity.
@ast
CD4 T cells in tumor immunity.
@en
CD4 T cells in tumor immunity.
@nl
P1476
CD4 T cells in tumor immunity.
@en
P2093
Mara Gerloni
Maurizio Zanetti
P2888
P356
10.1007/S00281-004-0193-Z
P577
2005-03-15T00:00:00Z
P6179
1023748482